199 related articles for article (PubMed ID: 16236817)
1. Structural determinants of pharmacological specificity between D(1) and D(2) dopamine receptors.
Lan H; Durand CJ; Teeter MM; Neve KA
Mol Pharmacol; 2006 Jan; 69(1):185-94. PubMed ID: 16236817
[TBL] [Abstract][Full Text] [Related]
2. Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology.
Schetz JA; Benjamin PS; Sibley DR
Mol Pharmacol; 2000 Jan; 57(1):144-52. PubMed ID: 10617689
[TBL] [Abstract][Full Text] [Related]
3. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
[TBL] [Abstract][Full Text] [Related]
4. Characterization of functional roles of DRY motif in the 2nd intracellular loop of dopamine D2 and D3 receptors.
Kim JH; Cho EY; Min C; Park JH; Kim KM
Arch Pharm Res; 2008 Apr; 31(4):474-81. PubMed ID: 18449505
[TBL] [Abstract][Full Text] [Related]
5. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
Patel S; Patel S; Marwood R; Emms F; Marston D; Leeson PD; Curtis NR; Kulagowski JJ; Freedman SB
Mol Pharmacol; 1996 Dec; 50(6):1658-64. PubMed ID: 8967990
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding.
Ehrlich K; Götz A; Bollinger S; Tschammer N; Bettinetti L; Härterich S; Hübner H; Lanig H; Gmeiner P
J Med Chem; 2009 Aug; 52(15):4923-35. PubMed ID: 19606869
[TBL] [Abstract][Full Text] [Related]
7. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
Jutkiewicz EM; Bergman J
J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.
Ryman-Rasmussen JP; Nichols DE; Mailman RB
Mol Pharmacol; 2005 Oct; 68(4):1039-48. PubMed ID: 15985612
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of N,N-di-n-propyl-5,6,7,8-tetrahydro-1 H-benz[f]benzimidazol-6-yl-amine and related congeners as dopaminergic ligands.
Dragović D; Soskić V; Joksimović J
Pharmazie; 1995 Oct; 50(10):678-80. PubMed ID: 7501691
[TBL] [Abstract][Full Text] [Related]
10. Link between dopamine D1 and D2 receptors in rat and human striatal tissues.
Seeman P; Tallerico T
Synapse; 2003 Mar; 47(4):250-4. PubMed ID: 12539197
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D(1) and D(2) receptors in the forebrain of dystonia musculorum mutant mice: an autoradiographic survey in relation to dopamine contents.
Ongali B; Ase AR; Hébert C; Amdiss F; Reader TA
Synapse; 2000 Jul; 37(1):1-15. PubMed ID: 10842346
[TBL] [Abstract][Full Text] [Related]
12. Investigation of cooperativity in the binding of ligands to the D(2) dopamine receptor.
Vivo M; Lin H; Strange PG
Mol Pharmacol; 2006 Jan; 69(1):226-35. PubMed ID: 16204468
[TBL] [Abstract][Full Text] [Related]
13. Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes.
Boeckler F; Lanig H; Gmeiner P
J Med Chem; 2005 Feb; 48(3):694-709. PubMed ID: 15689154
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine.
Cabedo N; Protais P; Cassels BK; Cortes D
J Nat Prod; 1998 Jun; 61(6):709-12. PubMed ID: 9644051
[TBL] [Abstract][Full Text] [Related]
15. Studies on the role of the receptor protein motifs possibly involved in electrostatic interactions on the dopamine D1 and D2 receptor oligomerization.
Łukasiewicz S; Faron-Górecka A; Dobrucki J; Polit A; Dziedzicka-Wasylewska M
FEBS J; 2009 Feb; 276(3):760-75. PubMed ID: 19143836
[TBL] [Abstract][Full Text] [Related]
16. Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D(1)-like receptors: studies with SK&F 83822.
Fujita S; Lee J; Kiguchi M; Uchida T; Cools AR; Waddington JL; Koshikawa N
Eur J Pharmacol; 2006 May; 538(1-3):94-100. PubMed ID: 16682023
[TBL] [Abstract][Full Text] [Related]
17. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography.
Seeman P; Tallerico T; Ko F
Synapse; 2003 Sep; 49(4):209-15. PubMed ID: 12827639
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of the human D5 dopamine receptor missense and nonsense variants: differences in dopamine binding affinities.
Cravchik A; Gejman PV
Pharmacogenetics; 1999 Apr; 9(2):199-206. PubMed ID: 10376767
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and properties of several heterocyclic dopaminergic ligands.
Kostić S; Soskić V; Joksimović J
Arzneimittelforschung; 1994 Jun; 44(6):697-702. PubMed ID: 7914413
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptors in the anterior insular cortex modulate long-term nociception in the rat.
Coffeen U; López-Avila A; Ortega-Legaspi JM; del Angel R; López-Muñoz FJ; Pellicer F
Eur J Pain; 2008 Jul; 12(5):535-43. PubMed ID: 17936656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
